Clinical Trials
20 trialsNCT02954874 2026-05-15
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05601440 2026-05-07
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03503799 2026-04-13
RESCUE
North Eastern German Society of Gynaecological Oncology
Active not recruiting
NCT07447440 2026-03-11
RESOLBE
Clinica Universidad de Navarra, Universidad de Navarra
Recruiting
NCT06718010 2026-01-21
The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
Fudan University
Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT06222957 2024-11-19
HEAT
Rigshospitalet, Denmark
Recruiting
NCT05592483 2024-11-07
DB RESPOND
AstraZeneca
Terminated
NCT06126003 2024-08-02
Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.
BioCorteX Inc
Terminated
NCT04857619 2024-07-11
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
AstraZeneca
Completed
NCT02101385 2023-09-28
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00002668 2023-06-22
Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer
Eastern Cooperative Oncology Group
Phase NA Terminated
NCT02733601 2023-04-03
BreCaReAl
AstraZeneca
Completed
NCT04807595 2023-03-06
Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status
AstraZeneca
Completed
NCT05730647 2023-02-16
GIM 23- POSTER
Consorzio Oncotech
Active not recruiting
NCT05250336 2022-02-22
Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Unknown
NCT02560311 2015-09-25
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis
University of Zurich
Unknown
NCT00445731 2014-09-08
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
University of Minnesota
Phase NA Completed
NCT00189631 2005-12-08
UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy
Association Européenne de Recherche en Oncologie
Phase 3 Unknown